When botulinum toxin is used correctly, the risk of complications is low. There are no long-term or life-threatening adverse effects related to botulinum toxin treatment for any cosmetic indication. Hemifacial spasm is a condition characterized by intermittent unilateral clonic or tonic contractions of the muscles of facial expression supplied by the facial nerve. The median time until the start of the last dose of DYSPORT was approximately one week and the median duration was approximately three weeks. Dysport can interact with cold or allergy medications, muscle relaxants, sleeping pills, bronchodilators, bladder or urine medications, irritable bowel medications, or injected antibiotics.
The effect of administering botulinum neurotoxin products, including DYSPORT, at the same time or several months apart is unknown. Of the 230 subjects treated with DYSPORT and tested for the presence of binding antibodies, 5 subjects tested positive at the start of treatment and 17 developed antibodies after treatment. The average dose of Dysport used was gradually reduced from the initial 130 units to 84 units for the sixth treatment. Injection site discomfort and injection site pain were common adverse reactions after administration of DYSPORT. Based on the analysis of the results of the treatments, Dysport can be used as effectively as Botox and the annual cost is lower. Table 11 lists the adverse reactions that occurred in ≥ 2% of patients in any DYSPORT dose group and more common than placebo in the double-blind study that evaluated the treatment of lower limb spasticity in adults.
Other adverse reactions with an incidence of less than 5% in the group of 500 DYSPORT units in the double-blind phase of clinical trials were dizziness in 3.5% of patients treated with Dysport and 1% of patients treated with placebo, and muscle atrophy in 1% of patients treated with Dysport and in none of the patients treated with placebo. Dysport for injection (AbobotulinumToxin), also called botulinum toxin type A, is made from the bacteria that cause botulism and is used to treat cervical dystonia (severe spasms in the neck muscles). Table 10 lists the adverse reactions that occurred in ≥ 2% of patients in any DYSPORT dose group and that were more common than placebo in double-blind studies evaluating the treatment of upper limb spasticity in adults. In conclusion, when used correctly, Dysport has no long-term or life-threatening adverse effects related to its use for any cosmetic indication. However, it is important to be aware that there are potential side effects associated with its use. It is also important to be aware that Dysport can interact with certain medications and that it can cause binding antibodies to develop in some people.
Therefore, it is important to discuss any potential risks with your doctor before starting treatment.
